Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) will announce third quarter 2025 financial results and host a conference call and live audio webcast on Tuesday, November 4, 2025 at 8:30 a.m. ET.
Phone participants must register online to receive a dial-in number and personal PIN; web participants can register at ir.amicusrx.com (recommended 15 minutes before the call). An archived webcast and slides will be posted on the company website shortly after the live event.
Investor and media contacts are listed for follow-up.
Details
News Market Reaction – FOLD
On Oct 23, the day this news came out, FOLD closed 0.58% below the previous close.
Data tracked by StockTitan Argus for the Oct 23 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to discuss financial results for the quarter ended September 30, 2025.
Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.
An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Brendan McEvoy
Executive Director, External Communications
bmcevoy@amicusrx.com
(609) 662-5005
FOLD–G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.